Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers Squibb & Co (NYSE: BMY) has posted Q3 revenues of $11.6 billion, an increase of 10%, in line with the consensus estimate of $11.58 billion.  Sales growth was driven by Revlimid (+11%), Eliquis (+15%), Opdivo (+7%), and a new product portfolio.

Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook

Shares of Bristol Myers Squibb Co. BMY, +0.74% gained 0.6% in premarket trading on Wednesday after the drug maker beat expectations for the quarter and saw sales rise for two of its top-selling products. The company had earnings of $1.5 billion, or 69 cents per share, in the third quarter of 2021, down from $1.8 billion, or 82 cents per share, in the same quarter a year ago.

Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter

Bristol Myers Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.

Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Third Quarter Financial Results for 2021

Bristol Myers Squibb Reports Third Quarter Financial Results for 2021

SAN FRANCISCO--(BUSINESS WIRE)---- $BMY #BMY--BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

Bristol Myers Squibb is scheduled to report its Q3 2021 results on Wednesday, October 27. We expect the company to likely post revenue and earnings slightly above the consensus estimates, primarily led by continued market share gains for its anticoagulant Eliquis, cancer drugs Opdivo and Yervoy.

What To Expect From Bristol Myers Squibb Stock After Q3 Results?

NEW YORK--(BUSINESS WIRE)---- $bmy #BMS--Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)

Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)

Aurinia Pharmaceuticals

Bristol Myers Squibb Co has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals Inc, Bloomberg News reported on Friday, citing people familiar with the matter.

Bristol Myers interested in buying Aurinia Pharma - Bloomberg News

Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.

What is in Store for Bristol-Myers (BMY) in Q3 Earnings?

The recent market pullback was a paltry 5.2% and left many blue-chip bargain hunters yearning for a rip-roaring correction. Fortunately, 90% of the S&P 500 fell into a correction, meaning incredible long-term buying opportunities are plentiful even with the market back to record highs.

3 Reasons To Invest Like Buffett And Buy Bristol Myers

Acceleron Pharma

Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter. Bristol-Myers holds an 11.5% stake in Acceleron.

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or.....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …

Cigna

Stock bargains can exist in both bull and bear markets alike. I present 2 blue-chips with moat-worthy businesses that are trading rather cheaply at the moment.

2 Buffett-Style Fat Pitches You Won't Want To Miss

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

Growing concerns regarding drug price controls are dragging down the stock price for many big pharmaceuticals.

Bristol-Myers Squibb: Oversold Big Pharma

Bristol-Myers Squibb has fallen nearly $13 in just a month due to irrational drug pricing fears.

Bristol-Myers Squibb: Now Is The Time

BMY stock slumped while Merck bounced back. Lawsuit hurting share price.

Why Bristol Myers Stock Offers More Than Just A 3.44% Dividend Yield

The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.

Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC

Amazon

Alibaba

Intel

GuruFocus' Most Broadly Held model portfolio consists of the 25 stocks that have the highest number of guru owners, rebalanced annually.

5 Undervalued Stocks Popular Among Gurus

AbbVie

Chevron

Kraft Heinz

Coca-Cola

Mastercard

Mondelez

Merck

Organon & Co

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Visa

Verizon

This Buffett holdings list from Kiplinger first appeared 8/17/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 10/13/21 YCharts data.

3 Buyable Dogs Bolster Buffett's October Dividend Holdings

Abbott Labs

America First Multifamily Investors

Annaly Capital

Pfizer

For high yield hunters, market corrections are an opportunity to enhance their income stream.

Make Money In Your Sleep: 3 Big Dividends To Buy Today

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Biogen

Vertex Pharmaceuticals

There are good reasons behind analysts' optimism about these stocks.

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

Global X Russell 2000 Covered Call ETF

Southern Company

After 32 weeks and $3,200, the Dividend Harvesting Portfolio is generating $220.29 in estimated annual income and $18.36 in monthly estimated income. In week 32, I added to my position in Southern Company and the Global X Russell 2000 Covered Call ETF.

Dividend Harvesting: Week 32 Update, $3,200 Allocated, $220.29 In Annual Dividends Yielding 6.91% With 48 Positions

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #DAYBREAK--Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study.....

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

News for Bristol-Myers Stock (BMY)